| 发明名称 | Methods and compositions related to clot-binding compounds | ||
| 摘要 | Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders. | ||
| 申请公布号 | US8912136(B2) | 申请公布日期 | 2014.12.16 |
| 申请号 | US201012973459 | 申请日期 | 2010.12.20 |
| 申请人 | Sanford-Burnham Medical Research Institute | 发明人 | Ruoslahti Erkki;Agemy Lilach;Kotamraju Venkata Ramana |
| 分类号 | A61K38/00;C07K14/755;C07K7/06;A61K45/06;A61K38/06;A61K9/127;A61K38/08;A61K9/16 | 主分类号 | A61K38/00 |
| 代理机构 | Jenkins, Wilson, Taylor & Hunt, P.A. | 代理人 | Jenkins, Wilson, Taylor & Hunt, P.A. |
| 主权项 | 1. A composition comprising a surface molecule selected from the group consisting of an iron oxide nanoworm, an iron oxide nanoparticle, an albumin nanoparticle, a liposome, a microparticle, and a fluorocarbon microbubble and at least one clot-binding compound, wherein the clot-binding compound comprises an amino acid sequence selected from the group consisting of C(NMe)REKA (SEQ ID NO:8), CR(NMe)EKA (SEQ ID NO:9), CR(CMe)EKA (SEQ ID NO:10), CRE(NMe)KA (SEQ ID NO:11), CRE(CMe)KA (SEQ ID NO:12), and CR(NMe)E(NMe)KA (SEQ ID NO: 13) and selectively binds to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors, wherein the clot-binding compound enhances the clotting in tumors compared to its unmodified derivative. | ||
| 地址 | LaJolla CA US | ||